

Instructions For Use

Ferritin Turbilatex (9+1) (Turbidimetric Method)

Cat no.	size
6104 101	50 TEST
6104 102	100 TEST
6104 103	200 TEST

INTENDED USE

Ferritin Turbi Latex Reagent is intended for the in vitro Quantitative diagnostic determination of Ferritin in human serum or plasma

PRINCIPLE OF THE METHOD

Ferritin-Turbilatex is a quantitative turbidimetric test for the measurement of ferritin in human serum or plasma.

Latex particles coated with specific anti-human ferritin are agglutinated when mixed with samples containing ferritin. The agglutination causes an absorbance change, dependent upon the ferritin contents of the sample that can be quantified by comparison from a calibrator of known ferritin concentration.

CLINICAL SIGNIFICANCE

Serum ferritin concentration usually reflects body iron stores and is considered one of the most reliable indicators of iron status of patients Whereas low serum concentrations of ferritin are always indicative of an iron deficiency, elevated concentrations can occur for variety of reasons. Thus, although elevated concentrations often indicate an excessive iron intake, they are also caused by liver disease, chronic inflammation and malignancies. Pregnant women, blood donors, hemodialysis patients, adolescents and children are groups particularly at risk.

REAGENTS

Reagent(R1)	Tris buffer 20 mmol/L, pH 8.2. Sodium azide 0.95 g/L
Reagent(R2)	Latex particles coated with anti-human ferritin, pH 8.2. Preservative
FERR-CAL	Ferritin Calibrator concentration is stated on the vial label. Ferritin control

PRECAUTIONS

Components from human origin have been tested and found to be negative for the presence of HBs Ag, HCV, and antibody to HIV (1/2). However handle cautiously as potentially infectious.

CALIBRATION

Use Ferritin Calibrator


The sensitivity of the assay and the target value of the calibrator have been standardized against the 3rd International Standard of Ferritin (94/572, 2008 WHO). Recalibrate when control results are out of specified tolerances, when using different lot of reagent and when the instrument is adjusted

Calibration curve: Prepare the following FERR calibrator dilutions in physiological saline. To obtain the concentration of each dilution, multiply using the dilution factor To obtain the concentration of each dilution, multiply using the dilution factor shown in the next table: As EX:-

Calibrator NO.	1	2	3	4	5
Calibrator concentrati on	0	65	130	260	520
Dilution method	Saline	25 μl cal + 175 μl saline	50 μl cal + 150 μl saline	100 μl cal + 100 μl saline	calibrato r
Test sample	45 µl	45 µl	45 µl	45 µl	45 µl

PREPARATION

Ferritin Calibrator: Reconstitute (\rightarrow) with 3.0 mL of distilled water. Mix gently and incubate at room temperature for about 10 minutes before testing. **Reconstituted Calibrator:** Stable 1 month at 2-8°C or 3 months at-20°C



STORAGE AND STABILITY

All the components of the kit are stable until the expiration date on the label when stored tightly closed at 2-8°C and contaminations are prevented during their use. Do not use reagents over the expiration date.

Reagent deterioration: Presence of particles and turbidity. Do not freeze

ADDITIONAL EQUIPMENT

-Thermostatic water bath at 37°C. -Spectrophotometer or photometer able to read at 540 nm.

SAMPLES

1. Fresh serum. Stable 7 days at 2-8°C or 3 months at -20°C

2. The samples with presence of fibrin should be centrifuged before testing. 3.Do

not use highly hemolized or lipemic samples.

PROCEDURE

1. Bring the working reagent and the photometer (cuvette holder) to 37°C.

2. Assay conditions:	
Mode :	FIXED TIME
Wavelength:	540nm (530-550)
Temperature:	37°C
Cuvette light path:	1 cm
Delay time:	5 sec
Measuring time:	300 sec
3. Adjust the instrument	to zero with distilled water.

4 Pipette into cuvette

4.1 ipette into euvette.	
(R1) Diluent (µL)	450
(R2) Latex (µL)	50
Calibrator or Sample (µL)	45

5. Mix and read the absorbance (A1) after **5 sec** and after **5 minutes** read the absorbance (A2).

CALCULATIONS

Calculate the absorbance difference (A2-A1) of each point of the calibration curve and plot the values obtained against the Ferritin concentration of each calibrator dilution. Ferritin concentration in the sample is calculated by interpolation of its (A2-A1) in the calibration curve.

(**Optional**) one point linear Calibration and using ferritin table conversion to get nonlinear value.

QUALITY CONTROL

Control Sera are recommended to monitor the performance of manual and automated assay procedures.

Each laboratory should establish its own Quality Control scheme and corrective actions if controls do not meet the acceptable tolerances.

REFERENCE VALUES

Men: 30 – 220 µg/L Children (6 months -15 years) 7-150 µg/L

Women: 20 - 110 µg/L

Each laboratory should establish its own reference range.

PERFORMANCE CHARACTERISTICS

Linearity limit: Up to 600 μ g/L. Samples with higher values should be diluted 1/3 with physiological saline and retested. The upper linearity limit increases as the sample volume and the sensitivity decrease.

Detection limit: 5.04 µg/L

Quantification limit: Values below 6.6 μ g/L may give non-reproducible results.

Prozone effect: No prozone effect was detected at least up to 9000 μ g/L. **Precision:** According to the EP5-A2 standards (CLSI), the reagent has been tested for 20 days, measuring each level per duplicate twice a day (n=80):

	Intra-assay (n= 20)			Inter-a	assay (n=	: 20)
Mean (µg/L)	35.0	115	290	35	115	290
SD	1.5	1.7	2.0	2.0	3.0	7.0
CV (%)	4.3	1.5	0.68	5.7	2.6	2.4

Method comparison:

The reagent was compared to another commercially available Ferritin reagent by testing 144 samples (male and female), with concentrations between 6.97 and 730 ug/L. The coefficient of correlation (r) was 0,988, and the equation y = 0.96x + 1.15


Performance characteristics depend on the analyzer used. **INTERFERENCES**

Bilirubin (10 mg/dL), hemoglobin (5 g/L), and rheumatoid factors (750 IU/mL), do not interfere. Lipids (≥ 2.5 g/L) do interfere. Other substances may interfere. **NOTES**

Clinical diagnosis should not be made on findings of a single test result, but should integrate both clinical and laboratory data.

BIBLIOGRAPHY

- 1. Knovich MA et al., Blood Rev. 2009 23(3):95-104.
- 2. Mazza J et al. Can Med Assoc J 1978; 119: 884-886
- Rodriguez Perez J et al. Revista Clinica Española 1980: 156 (1): 39-43
- Milman N et al. Eur J Haematol 1994: 53: 16-20.
 Young DS. Effects of drugs on clinical laboratory test, 5th ed. AACC Press, 1999



www.genesis-egy.com info@genesis-egy.com





CMC Medical device, C/ Horacio

IFU-FE-08

Rev. (2) 17/09/2023

Lengo n18 C.P 29006, Málaga-Spain